Ligand Announces Fourth Quarter and Full Year 2010 Consolidated Financial Results
Ligand Appoints John L. LaMattina to Board of Directors
Ligand to Report Fourth Quarter Results on February 15th
Ligand Acquires CyDex Pharmaceuticals
Ligand Forms Strategic Drug Development Alliance with Chiva Pharmaceuticals
Ligand Earns $1 Million Upfront Payment from Pfizer on Sublicensing of Tanaproget
Ligand Announces Positive Preclinical Data on Small Molecule Erythropoietin Receptor Agonists
Ligand Announces Presentation of Data from Multiple Studies of Dinaciclib by its Partner Merck at the ASH Annual Meeting
Ligand Reverse Stock Split Effective Today
Ligand Pharmaceuticals Announces Third Quarter Results
Ligand Announces 1-for-6 Reverse Stock Split
Ligand Announces Approval for Revolade(R) in Japan
Ligand Awarded $2 Million from U.S. Government Under the Patient Protection and Affordable Care Act
Ligand to Report Third Quarter Results on November 9
